Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
Status:
Recruiting
Trial end date:
2028-10-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of ALXN2220 in the treatment of
adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo
groups as assessed by the composite endpoint of all-cause mortality (ACM) and total
cardiovascular (CV) clinical events.